

UPDATED 3/7/2012

Preferred Drug List Committee Meeting Agenda, Open Session March 14th, 2012 10:00 a.m.

Meeting Location

HP Enterprise Services ~ Capital Room
6700 SW Topeka Blvd, Bldg. 283 J, Topeka, Kansas 66619

Board Members

Landa Colvin-Marion, Pharm. D.	Kristen Fink, Pharm.D.
Robert Haneke, Pharm.D.	Glenn Harte, Pharm.D.
Terry 'Lee' Mills, Jr., M.D.	Matthew Schlotterback, M.D.
Donna Sweet, M.D.	Dennis Tietze, M.D.

KDHE-DHCF Staff

Dr. Margaret Smith	Kelley Melton, Pharm.D.
Shelly Liby	Shea Robinson

HP Enterprise Services / HID Staff

Karen Kluczykowski, R.Ph.	Lisa Todd, R.Ph.
Nicole Churchwell, Pharm.D.	

ACS Staff

Bethany Noble, CPhT

- I. Welcome & Announcements
- II. Review & Approval of September 14, 2011 Meeting Minutes
- III. Adjunct Antiepileptics – Class Re-review: New Agents (Onfi)
 - a. Public Comment*
 - b. Committee Discussion/Recommendations
- IV. Diabetic Agents: Incretin Mimetics – New Class Review
 - a. Public Comment*
 - b. Committee Discussion/Recommendations

- V. Anti-hyperlipidemics: Bile Acid Sequestrants – New Class Review
 - a. Public Comment*
 - b. Committee Discussion/Recommendations

- VI. Fixed Dose Combinations for Diabetes – Class Re-review: New Agents (Janumet XR, Jentadueto, Juvisync)
 - a. Public Comment*
 - b. Committee Discussion/Recommendations

- VII. Fixed Dose Combination Products for Hypertension– Class Re-review: New Agent (Edarbyclor)
 - a. Public Comment*
 - b. Committee Discussion/Recommendations

- VIII. Non-benzodiazepine Sedative Hypnotics – Class Re-review: New Agents (Intermezzo)
 - a. Public Comment*
 - b. Committee Discussion/Recommendations

- IX. Urologic Agents: Anticholinergics – Class Re-review: New Agents (Anturol)
 - a. Public Comment*
 - b. Committee Discussion/Recommendations

- X. Intranasal Corticosteroids – Class Re-review: New Agent (Zetonna)
 - a. Public Comment*
 - b. Committee Discussion/Recommendations

- XI. Medicaid Reform Update
- XII. Public Comment Policy Update
- XIII. Selection of New Chairperson
- XIV. Open Public Comment
- XV. Adjourn

*Public Comment is limited to five minutes per product; additional time will be allowed at the Board’s discretion. Informal comments will be accepted from members of the audience at various points in the agenda.

****THIS AGENDA IS SUBJECT TO CHANGE.**